16 results about "Blood concentration" patented technology

The present application relates to the technical field of federated learning, and particularly to a blood drug concentration anomaly analysis method based on federated learning, comprising the following steps: a center server generates and issues a proxy data set without privacy risk to a plurality of medical institution clients; and receiving local prediction logits generated and uploaded by the plurality of medical institution clients after predicting the proxy data set by using local heterogeneous models. In the present application, a dynamically evolving global prototype memory bank is combined for anomaly judgment, a normal prototype benchmark reflecting the latest global state is constructed by periodically fusing feature distributions extracted by each node at different time stages, so that anomaly detection no longer depends on static or isolated rules, but is based on a dynamically updated and collectively agreed dynamic standard, thereby improving the robustness and accuracy of anomaly judgment.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

This invention relates to compounds of Formula I or salts thereof. The invention also provides the application of Formula I in the preparation of medicaments for treating JAK-related autoimmune diseases, inflammatory diseases, or cancers, which exhibit significant stability, maintain effective blood concentrations for a certain period, thereby prolonging the drug administration cycle, improving patient compliance, and reducing side effects caused by rapid drug release.

The present invention relates to a transdermal absorption preparation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone, and also shows good storage stability against heat, humidity, and light. According to the present invention, a transdermal absorption preparation containing tandospirone or a pharmaceutically acceptable salt thereof, and levulinic acid, which is superior in the skin permeability of tandospirone or a pharmaceutically acceptable salt thereof in the preparation, and shows good preservation stability against heat and light can be provided.

This invention discloses an intelligent drug scheduling method and system based on drug classification and joint constraint solving, belonging to the field of pharmaceutical information technology. The method includes: 1. Classifying drugs into four categories according to dosing strictness: blood concentration-dependent, local-acting, on-demand, and circadian rhythm-dependent, with each category corresponding to a different drug scheduling strictness strategy; 2. Extracting the independent constraints and inter-drug constraints for each drug, and performing multi-source verification and confidence labeling on the interval requirements; 3. Jointly solving the drug scheduling time for all drugs using the user's lifestyle as an anchor point; 4. Performing four-dimensional verification of the drug scheduling scheme based on interval rationality, dosing conditions, drug compatibility, and executability; 5. Supporting dynamic adjustments such as missed doses, adding medication, and changing medications. This invention solves the problems of existing medication reminder products that independently schedule each drug, cannot detect interval conflicts, do not consider differences in drug classification strictness, and do not anchor to lifestyle, significantly improving the safety and executability of drug scheduling in multi-drug use scenarios.

This invention provides an endoscopic system, program, and method for outputting blood flow information that can provide blood flow information without administering contrast agents, fluorescent agents, etc. [Solution] An endoscope system capable of acquiring blood concentration image data indicating blood concentration, comprising an output unit that outputs information regarding blood flow based on blood concentration image data acquired at multiple different time points.

This invention discloses a personalized target-controlled infusion system and method for cyclopofol based on population pharmacokinetics. The technical solution disclosed in this invention introduces body weight and age as covariates to optimize clearance calculation, achieving precise control of cyclopofol administration. This allows for accurate control of cyclopofol blood concentration in patients, addressing the problem of large individual differences in medication use, and achieving safe and effective anesthesia management. Compared with existing technologies, its advantages include: personalized administration: adjusting clearance by body weight and age reduces inter-individual variability and improves blood concentration stability; precise control: based on a three-compartment model and covariate screening, accurate prediction and control of cyclopofol target-controlled infusion are achieved; clinical applicability: suitable for various administration methods such as intravenous bolus and infusion, providing anesthesiologists with a reliable tool.

Blood loss is quantified using a medical waste collection system, which includes a receiver removably coupled to a manifold. The manifold and / or the medical waste collection system is coupled to a fluid characterization module having sensor components to detect features representing the blood concentration within the fluid. The sensor components may include an emitter and a sensor to detect light transmitted and scattered by the fluid in a suction path or detection window. The first emitter may be a visible light LED, and the second emitter may be an infrared LED. A flow guide may provide a tortuous path within the manifold and facilitate the separation of gas and liquid within the fluid. Quantifying blood loss may include determining the blood concentration within the fluid and determining the volume of fluid collected. The sensor gain may be adjusted based on the transmittance of the collected fluid.

A substance-in-blood concentration measurement device for measuring concentration of a substance in blood of a living body, including: a target placement unit on which the living body that includes a measurement target portion is placed; a light emission unit that irradiates the measurement target portion with a laser beam; a photodetector that receives reflected light from the measurement target portion and detects intensity of the reflected light; and a condenser lens disposed on an optical path of the reflected light between the measurement target portion and the photodetector. On the optical path from the measurement target portion to the photodetector, in a section from the target placement unit to the photodetector, the reflected light propagates through space, except where transmitted through the condenser lens, and the condenser lens forms an image of the reflected light on the photodetector.

The present invention relates to an oral immediate-release formulation comprising ilaprazole with improved stability as an active ingredient and a method for preparing same, wherein the present invention relates to an oral immediate-release formulation and a method for preparing same, the oral immediate-release formulation comprising ilaprazole and a stabilizer in an inner core portion thereof and an antacid in an outer layer portion thereof, in which the oral immediate-release formulation has improved compounding stability by suppressing contact between the inner core portion and the outer layer portion through coating on the inner core portion, has excellent stability by minimizing the amount of related substances generated, and has a fast drug effect (the time to reach maximum blood concentration (Tmax) ranges from 0.3 hours to 0.8 hours) and excellent stability, through the rapid antacid effect of the antacid.

The blood purification system connected to the ECMO system having an ECMO blood pump and an artificial lung includes a water removal control unit that maintains the concentration of blood circulating through the blood purification system at a predetermined concentration when the rate of change of the flow of blood in the ECMO system exceeds a predetermined threshold.

It can remain in the bloodstream for a long period, allowing for the maintenance of high blood concentrations of the active ingredient over extended periods. To provide a liposome formulation containing a CD1d ligand compound that can perform the necessary functions. [Solution] The present invention provides a liposome formulation comprising a group of liposomes containing a CD1d ligand compound, wherein the average particle size of the group of liposomes is 90 to 110 nm, and the polydispersity of the particle size distribution is 0.2 or less. The present invention also provides a method for producing the formulation.

The application discloses a real-time bleeding volume estimation and early warning system in laparoscopic hepatectomy, and belongs to the technical field of medical monitoring. The system comprises an image acquisition module, an aspiration flow sensor, a blood concentration sensor, a data processing module and an early warning module; the data processing module is connected with each sensor, and comprises a three-dimensional reconstruction unit, an image segmentation unit and a bleeding volume calculation unit. The three-dimensional reconstruction unit reconstructs a three-dimensional surface model of a surgical area according to an image sequence, the image segmentation unit segments a blood coverage area and maps the blood coverage area to the three-dimensional model to obtain three-dimensional distribution information of blood; the bleeding volume calculation unit calculates the volume of pure blood sucked according to the aspiration flow and the blood concentration, and calculates the total bleeding volume in combination with the residual blood volume; the early warning module issues an early warning when the total bleeding volume or the bleeding rate exceeds a threshold value. The application realizes multi-source data fusion and three-dimensional space analysis of intraoperative bleeding volume, and can accurately estimate the total bleeding volume and dynamically issue an early warning.

This invention discloses a gelatin-based hemostatic powder with high osmotic pressure properties and its preparation method. The hemostatic powder is a porous gelatin-based material grafted with high-osmotic-pressure anionic functional groups such as sulfonic acid groups or their derivatives. The sulfonic acid groups or their derivatives endow the hemostatic powder with negative charge and high osmotic pressure properties, thereby achieving a dual hemostatic effect of osmotic pressure-driven blood concentration and negative charge enrichment to activate coagulation factors. The strong dissociation properties of the sulfonic acid groups or their derivatives endow the material with a surface negative potential of -20 to -50 mV and a high osmotic pressure of 0.30 to 0.55 Osmol / kg, achieving a pressure of 40 to 60 g·g. ‑ ¹ water absorption ratio and 0.15–0.20 g·g ‑ ¹·min ‑ ¹ Rapid water absorption. The preparation method of this invention involves activating the carboxyl group of gelatin and grafting a functional monomer containing a primary amino group, followed by purification, freeze-drying, and grinding. This invention achieves dual hemostatic effects of osmotic pressure-driven blood concentration and negatively charged enrichment to activate coagulation factors, making it suitable for wound hemostasis of arterial, venous, and organ bleeding.

This invention discloses a quantitative analysis method for the blood concentrations of HYQ-169 and prednisolone and its application, belonging to the fields of medical testing and pharmaceutical analysis. The quantitative analysis method includes the following steps: preparing standard curve samples and quality control samples; adding internal standard solution; extracting with ethyl acetate; drying the supernatant and reconstituteing; separating using SPE; drying the fraction and reconstituteing again; detecting using UPLC-MS / MS; establishing a standard curve and obtaining a regression equation; adding internal standard solution to the plasma sample to be tested and processing it in the same way; calculating the blood concentrations of HYQ-169 and prednisolone according to the regression equation. This invention can simultaneously perform quantitative detection of two drug components with significantly different chemical properties in a single analysis, with high sensitivity, high accuracy, and fast analysis speed, providing a foundation for preclinical and clinical pharmacokinetic studies of HYQ-169.

This invention provides a sustained-release formulation of β-hydroxybutyric acid (BHA) or its salts, comprising the following components by weight percentage: 40-50% BHA or its salts, 40-60% sustained-release matrix material, and 1-3% excipients. The product of this invention exhibits excellent dispersibility in water and enables the slow release of BHA or its salts, maintaining a stable and effective blood concentration in vivo for a relatively long period. This is of great significance for the practical application of BHA and its salts.